Literature DB >> 17579053

Potential of transfected muscle cells to contribute to DNA vaccine immunogenicity.

Hidekazu Shirota1, Lev Petrenko, Choongman Hong, Dennis M Klinman.   

Abstract

The mechanism(s) by which DNA vaccines trigger the activation of Ag-specific T cells is incompletely understood. A series of in vivo and in vitro experiments indicates plasmid transfection stimulates muscle cells to up-regulate expression of MHC class I and costimulatory molecules and to produce multiple cytokines and chemokines. Transfected muscle cells gain the ability to directly present Ag to CD8 T cells through an IFN-regulatory factor 3-dependent process. These findings suggest that transfected muscle cells at the site of DNA vaccination may contribute to the magnitude and/or duration of the immune response initiated by professional APCs.

Mesh:

Substances:

Year:  2007        PMID: 17579053     DOI: 10.4049/jimmunol.179.1.329

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells.

Authors:  Godwin Nchinda; Janelle Kuroiwa; Margarita Oks; Christine Trumpfheller; Chae Gyu Park; Yaoxing Huang; Drew Hannaman; Sarah J Schlesinger; Olga Mizenina; Michel C Nussenzweig; Klaus Uberla; Ralph M Steinman
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

2.  DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.

Authors:  Geoffrey J Gorse; Mark J Newman; Allan deCamp; Christine Mhorag Hay; Stephen C De Rosa; Elizabeth Noonan; Brian D Livingston; Jonathan D Fuchs; Spyros A Kalams; Farah L Cassis-Ghavami
Journal:  Clin Vaccine Immunol       Date:  2012-03-07

3.  Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection.

Authors:  Tae Heung Kang; Archana Monie; Lee S-F Wu; Xiaowu Pang; Chien-Fu Hung; T-C Wu
Journal:  Vaccine       Date:  2010-12-04       Impact factor: 3.641

4.  Electrotransfection and lipofection show comparable efficiency for in vitro gene delivery of primary human myoblasts.

Authors:  Tomaz Mars; Marusa Strazisar; Katarina Mis; Nejc Kotnik; Katarina Pegan; Jasna Lojk; Zoran Grubic; Mojca Pavlin
Journal:  J Membr Biol       Date:  2014-12-23       Impact factor: 1.843

5.  Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells.

Authors:  Yuko Shirota; Hidekazu Shirota; Dennis M Klinman
Journal:  J Immunol       Date:  2012-01-09       Impact factor: 5.422

6.  Direct presentation regulates the magnitude of the CD8+ T cell response to cell-associated antigen through prolonged T cell proliferation.

Authors:  Angela M Tatum; Alan M Watson; Todd D Schell
Journal:  J Immunol       Date:  2010-07-26       Impact factor: 5.422

7.  Toxoplasma gondii: immune response and protective efficacy induced by ROP16/GRA7 multicomponent DNA vaccine with a genetic adjuvant B7-2.

Authors:  Qi Liu; Fuwu Wang; Guan Wang; Qunli Zhao; Juan Min; Shuai Wang; Hua Cong; Ying Li; Shenyi He; Huaiyu Zhou
Journal:  Hum Vaccin Immunother       Date:  2013-10-07       Impact factor: 3.452

8.  Contribution of IRF-3 mediated IFNbeta production to DNA vaccine dependent cellular immune responses.

Authors:  Hidekazu Shirota; Lev Petrenko; Toshio Hattori; Dennis M Klinman
Journal:  Vaccine       Date:  2009-02-10       Impact factor: 3.641

9.  A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines.

Authors:  John J Suschak; Shixia Wang; Katherine A Fitzgerald; Shan Lu
Journal:  J Immunol       Date:  2015-11-20       Impact factor: 5.422

10.  Trial watch: DNA vaccines for cancer therapy.

Authors:  Laura Senovilla; Erika Vacchelli; Pauline Garcia; Alexander Eggermont; Wolf Hervé Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-04-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.